Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX : NSDQ)

• Company Description    Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $4.77 Daily Weekly Monthly 20 Day Moving Average: 27,214 shares Shares Outstanding: 2.01 (millions) Market Capitalization: $9.58 (millions) Beta: 1.61 52 Week High: $23.50 52 Week Low: $4.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.75% -20.82% 12 Week -43.95% -48.18% Year To Date -66.94% -69.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 42127 Pleasant Forest Court - Ashburn,VA 20148 USA ph: 703-980-4182 fax: 972-9767-8750 ir@cellectbio.com https://quoinpharma.com

• General Corporate Information    Officers Michael Myers - Chairman and Chief Executive Officer Denise Carter - Director and Chief Operating Officer Sally Lawlor - Chief Financial Officer Joseph Cooper - Director James Culverwell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74907L409 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 2.01 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.61 Market Capitalization: $9.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.38 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.09 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 72.77% vs. Previous Quarter: 88.04% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -489.85 12/31/25 - -535.00 09/30/25 - -334.41 ROA 03/31/26 - -221.29 12/31/25 - -223.99 09/30/25 - -125.15 Current Ratio 03/31/26 - 2.87 12/31/25 - 3.61 09/30/25 - 1.04 Quick Ratio 03/31/26 - 2.87 12/31/25 - 3.61 09/30/25 - 1.04 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 4.37 12/31/25 - 15.64 09/30/25 - -2.07 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - -

Powered by Zacks Investment Research ©